VT-1161 Protects Immunosuppressed Mice from Rhizopus arrhizus var. arrhizus Infection.

Abstract

We studied the efficacy of the investigational drug VT-1161 against mucormycosis. VT-1161 had more potent in vitro activity against Rhizopus arrhizus var. arrhizus than against R. arrhizus var. delemar. VT-1161 treatment demonstrated dose-dependent plasma drug levels with prolonged survival time and lowered tissue fungal burden in immunosuppressed mice infected with R. arrhizus var. arrhizus and was as effective as high-dose liposomal amphotericin B treatment. These results support further development of VT-1161 against mucormycosis.

• Authors: Teclegiorgis Gebremariam, Nathan P Wiederhold, Annette W Fothergill, Edward P Garvey, William J Hoekstra, Robert J Schotzinger, Thomas F Patterson, Scott G Filler, Ashraf S Ibrahim
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 59 Issue 12 Pg. 7815-7 (Dec 2015) ISSN: 1098-6596 [Electronic] United States
• PMID: 26369977 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
• Copyright: Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Chemical References

• Antifungal Agents
• Pyridines
• Tetrazoles
• VT-1161
• liposomal amphotericin B
• Amphotericin B

Topics

• Amphotericin B (pharmacology)
• Animals
• Antifungal Agents (blood, pharmacokinetics, pharmacology)
• Immunocompromised Host
• Male
• Mice
• Mice, Inbred ICR
• Microbial Sensitivity Tests
• Mucormycosis (drug therapy, immunology, microbiology, mortality)
• Pyridines (blood, pharmacokinetics, pharmacology)
• Rhizopus (drug effects, growth & development)
• Species Specificity
• Survival Analysis
• Tetrazoles (blood, pharmacokinetics, pharmacology)